Qatar Tribune's 21 September Doha note said Sidra Medicine highlighted a Genome Medicine article on multi-threshold polygenic risk and hippocampal cognitive-decline prediction, led by Mohamed Janahi with UCL colleagues. Janahi said the work does not diagnose Alzheimer's disease.
On 21 September Qatar Tribune in Doha marked World Alzheimer's Day by pointing to a Sidra Medicine Genome Medicine article on multi-threshold polygenic risk and hippocampal prediction of cognitive decline. Mohamed Janahi led the work in Younes Mokrab's laboratory, with Andre Altmann's UCL group listed as collaborators. The paper, as the newspaper describes it, puts a large set of genome-wide variants into imaging models that flag impairment and later decline.[1]
The Tribune says the models used nearly 24,000 UK Biobank volunteers and were then checked in about 3,000 people drawn from Alzheimer's Disease Neuroimaging Initiative (ADNI) plus European Prevention of Alzheimer's Dementia (EPAD). Janahi is quoted saying the work does not diagnose Alzheimer's disease. The same article, in a UCL in-press PDF, was received in October 2025 and accepted in July 2026. The Tribune note does not pin the journal issue on 21 September. This edition is using a day-marking newspaper file, not a new trial readout.[1]
The model gathers genetic variants associated with hippocampal volume into a single polygenic score; Janahi said it is not a diagnostic test and does not diagnose the disease. The score was built on roughly 24,000 UK Biobank volunteers and about 3,000 people from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and European Prevention of Alzheimer's Dementia (EPAD) studies. The findings rest on an already accepted Genome Medicine article; the day's announcement reports no new clinical result.[1]
